Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with Carbon-ion Radiotherapy for Cervical Adenocarcinoma
NCT06805864Phase 2Not yet recruiting
- Sponsor
- Gunma University
- Start
- Feb 2025
- Primary completion
- Dec 2029
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in cervical adenocarcinoma, cervical adenosquamous carcinoma (ASC), sponsored by Gunma University. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
03
Conditions
cervical adenocarcinomacervical adenosquamous carcinoma (ASC)
Beyond the preview
Go deeper on NCT06805864.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06805864.